Absci Q2 revenue falls and misses analyst expectations

Absci Q2 revenue falls and misses analyst expectations 


Overview

  • US biopharma firm's Q2 revenue fell and missed analyst expectations

  • Net loss widened as R&D expenses rose due to advancing internal programs

  • Company completed $100 mln offering, including $40 mln investment from Eli Lilly


Outlook

  • Absci expects interim proof-of-concept data for ABS-201 in pattern hair loss in H2 2026

  • Company plans full proof-of-concept data for ABS-201 in pattern hair loss in early 2027

  • Absci expects to initiate Phase 2 trial for endometriosis in Q4 2026, with data in H2 2027


Result Drivers

  • R&D SPENDING - Co said higher research and development expenses were driven by advancement of internal programs, including clinical development of ABS-201

  • POSITIVE TRIAL DATA - Co reported favorable safety and tolerability in interim Phase 1 data for ABS-201, supporting potential for convenient dosing

  • CASH INFUSION - Co completed $100 mln offering, including $40 mln strategic investment from Eli Lilly, extending funding into H2 2028


Company press release: ID:nGNX9vLP72


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$318,000

$1.17 mln (7 Analysts)

Q2 Net Loss

$33.21 mln

Q2 Loss Per Basic Share

$0.21

Q2 Operating Expenses

$34.48 mln

Q2 Operating Income

-$34.16 mln

Q2 Pretax Loss

$33.17 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Absci Corp is $14.00, about 55.4% above its August 10 closing price of $9.01


Reuters Recommended Reads

  • Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs

  • Aug 10 - Eli Lilly's weight-loss pill secures first European nod in Britain

  • Aug 10 - Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AbSci

See all news